LOXO-305, A Next Generation Reversible BTK Inhibitor, for Overcoming Acquired Resistance to Irreversible BTK Inhibitors
Abstract
The irreversible BTK inhibitors ibrutinib and acalabrutinib have transformed the treatment of several B-cell malignancies. However, their clinical benefit is limited by off-target toxicity, leading to high rates of treatment discontinuation, and acquired resistance, due to BTK C481 substitutions that prevent irreversible BTK...
Paper Details
Title
LOXO-305, A Next Generation Reversible BTK Inhibitor, for Overcoming Acquired Resistance to Irreversible BTK Inhibitors
Published Date
Sep 1, 2018
Volume
18
Pages
S216 - S216
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History